These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 35459256)

  • 1. Antibody-mediated delivery of a viral MHC-I epitope into the cytosol of target tumor cells repurposes virus-specific CD8
    Jung K; Son MJ; Lee SY; Kim JA; Ko DH; Yoo S; Kim CH; Kim YS
    Mol Cancer; 2022 Apr; 21(1):102. PubMed ID: 35459256
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expansion of cytomegalovirus pp65 and IE-1 specific cytotoxic T lymphocytes for cytomegalovirus-specific immunotherapy following allogeneic stem cell transplantation.
    Bao L; Dunham K; Stamer M; Mulieri KM; Lucas KG
    Biol Blood Marrow Transplant; 2008 Oct; 14(10):1156-1162. PubMed ID: 18804046
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficient identification of HLA-A*2402-restricted cytomegalovirus-specific CD8(+) T-cell epitopes by a computer algorithm and an enzyme-linked immunospot assay.
    Kuzushima K; Hayashi N; Kimura H; Tsurumi T
    Blood; 2001 Sep; 98(6):1872-81. PubMed ID: 11535524
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recruitment of Oligoclonal Viral-Specific T cells to Kill Human Tumor Cells Using Single-Chain Antibody-Peptide-HLA Fusion Molecules.
    Noy R; Haus-Cohen M; Oved K; Voloshin T; Reiter Y
    Mol Cancer Ther; 2015 Jun; 14(6):1327-35. PubMed ID: 25852061
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The efficiency of human cytomegalovirus pp65(495-503) CD8+ T cell epitope generation is determined by the balanced activities of cytosolic and endoplasmic reticulum-resident peptidases.
    Urban S; Textoris-Taube K; Reimann B; Janek K; Dannenberg T; Ebstein F; Seifert C; Zhao F; Kessler JH; Halenius A; Henklein P; Paschke J; Cadel S; Bernhard H; Ossendorp F; Foulon T; Schadendorf D; Paschen A; Seifert U
    J Immunol; 2012 Jul; 189(2):529-38. PubMed ID: 22706083
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Co-ordinated isolation of CD8(+) and CD4(+) T cells recognizing a broad repertoire of cytomegalovirus pp65 and IE1 epitopes for highly specific adoptive immunotherapy.
    Zandvliet ML; van Liempt E; Jedema I; Veltrop-Duits LA; Willemze R; Guchelaar HJ; Falkenburg JH; Meij P
    Cytotherapy; 2010 Nov; 12(7):933-44. PubMed ID: 20078388
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HLA tetramers and anti-CMV immune responses: from epitope to immunotherapy.
    Chen FE; Aubert G; Travers P; Dodi IA; Madrigal JA
    Cytotherapy; 2002; 4(1):41-8. PubMed ID: 11953040
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The matrix protein pp65(341-350): a peptide that induces ex vivo stimulation and in vitro expansion of CMV-specific CD8+ T cells in subjects bearing either HLA-A*2402 or A*0101 allele.
    Provenzano M; Lim JB; Mocellin S; Monsurro V; Bettinotti M; Marincola FM; Stroncek DF
    Transfusion; 2003 Nov; 43(11):1567-74. PubMed ID: 14617317
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Refining human T-cell immunotherapy of cytomegalovirus disease: a mouse model with 'humanized' antigen presentation as a new preclinical study tool.
    Lemmermann NA; Reddehase MJ
    Med Microbiol Immunol; 2016 Dec; 205(6):549-561. PubMed ID: 27539576
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical-scale isolation of 'minimally manipulated' cytomegalovirus-specific donor lymphocytes for the treatment of refractory cytomegalovirus disease.
    Odendahl M; Grigoleit GU; Bönig H; Neuenhahn M; Albrecht J; Anderl F; Germeroth L; Schmitz M; Bornhäuser M; Einsele H; Seifried E; Busch DH; Tonn T
    Cytotherapy; 2014 Sep; 16(9):1245-56. PubMed ID: 25108651
    [TBL] [Abstract][Full Text] [Related]  

  • 11. T cell receptor-targeted immunotherapeutics drive selective in vivo HIV- and CMV-specific T cell expansion in humanized mice.
    Li M; Garforth SJ; O'Connor KE; Su H; Lee DM; Celikgil A; Chaparro RJ; Seidel RD; Jones RB; Arav-Boger R; Almo SC; Goldstein H
    J Clin Invest; 2021 Dec; 131(23):. PubMed ID: 34673568
    [TBL] [Abstract][Full Text] [Related]  

  • 12. K562-Derived Whole-Cell Vaccine Enhances Antitumor Responses of CAR-Redirected Virus-Specific Cytotoxic T Lymphocytes In Vivo.
    Caruana I; Weber G; Ballard BC; Wood MS; Savoldo B; Dotti G
    Clin Cancer Res; 2015 Jul; 21(13):2952-62. PubMed ID: 25691731
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Programmed Death-Ligand 1 on Antigen-presenting Cells Facilitates the Induction of Antigen-specific Cytotoxic T Lymphocytes: Application to Adoptive T-Cell Immunotherapy.
    Goto T; Nishida T; Takagi E; Miyao K; Koyama D; Sakemura R; Hanajiri R; Watanabe K; Imahashi N; Terakura S; Murata M; Kiyoi H
    J Immunother; 2016 Oct; 39(8):306-15. PubMed ID: 27548033
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytomegalovirus-specific cytokine-induced killer cells: concurrent targeting of leukemia and cytomegalovirus.
    Pfirrmann V; Oelsner S; Rettinger E; Huenecke S; Bonig H; Merker M; Wels WS; Cinatl J; Schubert R; Klingebiel T; Bader P
    Cytotherapy; 2015 Aug; 17(8):1139-51. PubMed ID: 26072027
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase I-II trial to examine the toxicity of CMV- and EBV-specific cytotoxic T lymphocytes when used for prophylaxis against EBV and CMV disease in recipients of CD34-selected/T cell-depleted stem cell transplants.
    Lucas KG; Sun Q; Burton RL; Tilden A; Vaughan WP; Carabasi M; Salzman D; Ship A
    Hum Gene Ther; 2000 Jul; 11(10):1453-63. PubMed ID: 10910142
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vaccine-induced CD8 T cells are redirected with peptide-MHC class I-IgG antibody fusion proteins to eliminate tumor cells in vivo.
    Fischer C; Munks MW; Hill AB; Kroczek RA; Bissinger S; Brand V; Schmittnaegel M; Imhof-Jung S; Hoffmann E; Herting F; Klein C; Knoetgen H
    MAbs; 2020; 12(1):1834818. PubMed ID: 33151105
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epitope-specific in vivo protection against cytomegalovirus disease by CD8 T cells in the murine model of preemptive immunotherapy.
    Böhm V; Podlech J; Thomas D; Deegen P; Pahl-Seibert MF; Lemmermann NA; Grzimek NK; Oehrlein-Karpi SA; Reddehase MJ; Holtappels R
    Med Microbiol Immunol; 2008 Jun; 197(2):135-44. PubMed ID: 18340461
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Delivery of foreign cytotoxic T lymphocyte epitopes to tumor tissues for effective antitumor immunotherapy against pre-established solid tumors in mice.
    Kavunja HW; Lang S; Sungsuwan S; Yin Z; Huang X
    Cancer Immunol Immunother; 2017 Apr; 66(4):451-460. PubMed ID: 28011995
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detailed analysis of cytomegalovirus (CMV)-specific T cells expanded for adoptive immunotherapy of CMV infection following allogeneic stem cell transplantation for malignant disease.
    Hobeika A; Osada T; Serra D; Peplinski S; Hanson K; Tanaka Y; Niedzwiecki D; Chao N; Rizzieri D; Lyerly H; Clay T; Morse M
    Cytotherapy; 2008; 10(3):289-302. PubMed ID: 18418774
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of pp65-specific TCR-T cell therapy in treating cytomegalovirus infection after hematopoietic stem cell transplantation.
    Liu G; Chen H; Cao X; Jia L; Rui W; Zheng H; Huang D; Liu F; Liu Y; Zhao X; Lu P; Lin X
    Am J Hematol; 2022 Nov; 97(11):1453-1463. PubMed ID: 36054234
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.